TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸AEMD

Aethlon Medical, Inc. - Common Stock

NASDAQ
$0.71
▼ $1.50 (-67.9%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $3.44L $0.65-75.3%
$3.44$2.88$2.32$1.77$1.21$0.65$0.71
RSI (14)
Intraday · 15-minStrong sell-45RSI 40DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong sell-45
RSI (14)21
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$0.65
Resistance
$2.23
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 21 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
-28.6%
Buy & hold
-90.8%
Trades
5
Win rate
0%

$100,000.00 invested would be worth $71,446.98 (-28.6%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Aethlon Medical, Inc.· Medical Devices

source: yahoo

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
Employees
9
Headquarters
San Diego, United States
www.aethlonmedical.com ↗

Fundamentals· Energy

demo data

Live data was unavailable (the free feed can be rate-limited or blocked by region/host), so sample figures are shown. Set FINNHUB_API_KEY for a reliable fallback.

Market cap
$807.58B
P/E
24.8
P/B
5.1
EPS
$16.21
Div yield
2.7%
Profit margin
17.8%
ROE
20.7%
Debt / Equity
0.49
Beta
1.50
52-week range
$281.89 – $503.38
52-week low · $281.890% of rangehigh · $503.38

Recent news

News sentiment:— Neutral0↑ · 0↓ · 8–
  • Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®— Neutral
    PR Newswire · 26 Jun 2026
  • Aethlon Medical advances Hemopurifier study as final trial cohort nears completion— Neutral
    Proactive · 17 Jun 2026
  • Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...— Neutral
    GuruFocus.com · 17 Jun 2026

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Fundamental data is informational only — not investment advice.

AEMD: Clinical Study Advances to Final Cohort; Preclinical Activities Expand
— Neutral
Zacks Small Cap Research · 11 Jun 2026
  • Aethlon (AEMD) Q4 2026 Earnings Transcript— Neutral
    Motley Fool · 10 Jun 2026
  • Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update— Neutral
    PR Newswire · 10 Jun 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.